Trapidil

DB09283

small molecule experimental

Deskripsi

Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.

Struktur Molekul 2D

Berat 205.265
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].
Volume Distribusi -
Klirens (Clearance) The apparent clearance is 179 mL/min for a single dose and 273 mL/min for steady state dosing [A19770].

Absorpsi

Trapidil has a Tmax of 1 h A19770.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

419 Data
Apixaban The risk or severity of adverse effects can be increased when Trapidil is combined with Apixaban.
Dasatinib Dasatinib may increase the anticoagulant activities of Trapidil.
Ursodeoxycholic acid The risk or severity of adverse effects can be increased when Trapidil is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of adverse effects can be increased when Trapidil is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of adverse effects can be increased when Trapidil is combined with Cholic Acid.
Glycocholic acid The risk or severity of adverse effects can be increased when Trapidil is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of adverse effects can be increased when Trapidil is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of adverse effects can be increased when Trapidil is combined with Taurocholic acid.
Obeticholic acid The risk or severity of adverse effects can be increased when Trapidil is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of adverse effects can be increased when Trapidil is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of adverse effects can be increased when Trapidil is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of adverse effects can be increased when Trapidil is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of adverse effects can be increased when Trapidil is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of adverse effects can be increased when Trapidil is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of adverse effects can be increased when Trapidil is combined with Hyodeoxycholic Acid.
Glucosamine Glucosamine may increase the antiplatelet activities of Trapidil.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Trapidil is combined with Ibritumomab tiuxetan.
Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Trapidil.
Obinutuzumab The risk or severity of adverse effects can be increased when Trapidil is combined with Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the antiplatelet activities of Trapidil.
Rivaroxaban Trapidil may increase the anticoagulant activities of Rivaroxaban.
Tipranavir Tipranavir may increase the antiplatelet activities of Trapidil.
Urokinase Trapidil may increase the anticoagulant activities of Urokinase.
Vitamin E Vitamin E may increase the antiplatelet activities of Trapidil.
Pentosan polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Trapidil.
Limaprost Limaprost may increase the antiplatelet activities of Trapidil.
Omega-3 fatty acids Omega-3 fatty acids may increase the antiplatelet activities of Trapidil.
Tositumomab The risk or severity of adverse effects can be increased when Trapidil is combined with Tositumomab.
Lepirudin The risk or severity of bleeding can be increased when Trapidil is combined with Lepirudin.
Bivalirudin The risk or severity of bleeding can be increased when Trapidil is combined with Bivalirudin.
Alteplase The risk or severity of bleeding can be increased when Trapidil is combined with Alteplase.
Reteplase The risk or severity of bleeding can be increased when Trapidil is combined with Reteplase.
Anistreplase The risk or severity of bleeding can be increased when Trapidil is combined with Anistreplase.
Tenecteplase The risk or severity of bleeding can be increased when Trapidil is combined with Tenecteplase.
Abciximab The risk or severity of bleeding can be increased when Trapidil is combined with Abciximab.
Drotrecogin alfa The risk or severity of bleeding can be increased when Trapidil is combined with Drotrecogin alfa.
Streptokinase The risk or severity of bleeding can be increased when Trapidil is combined with Streptokinase.
Dicoumarol The risk or severity of bleeding can be increased when Trapidil is combined with Dicoumarol.
Argatroban The risk or severity of bleeding can be increased when Trapidil is combined with Argatroban.
Ardeparin The risk or severity of bleeding can be increased when Trapidil is combined with Ardeparin.
Phenindione The risk or severity of bleeding can be increased when Trapidil is combined with Phenindione.
Fondaparinux The risk or severity of bleeding can be increased when Trapidil is combined with Fondaparinux.
Warfarin The risk or severity of bleeding can be increased when Trapidil is combined with Warfarin.
Phenprocoumon The risk or severity of bleeding can be increased when Trapidil is combined with Phenprocoumon.
Dipyridamole The risk or severity of bleeding can be increased when Trapidil is combined with Dipyridamole.
Heparin The risk or severity of bleeding can be increased when Trapidil is combined with Heparin.
Enoxaparin The risk or severity of bleeding can be increased when Trapidil is combined with Enoxaparin.
Epoprostenol The risk or severity of bleeding can be increased when Trapidil is combined with Epoprostenol.
Acenocoumarol The risk or severity of bleeding can be increased when Trapidil is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Trapidil is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Trapidil is combined with Coumarin.
Ximelagatran The risk or severity of bleeding can be increased when Trapidil is combined with Ximelagatran.
Desmoteplase The risk or severity of bleeding can be increased when Trapidil is combined with Desmoteplase.
Defibrotide The risk or severity of bleeding can be increased when Trapidil is combined with Defibrotide.
Ancrod The risk or severity of bleeding can be increased when Trapidil is combined with Ancrod.
Beraprost The risk or severity of bleeding can be increased when Trapidil is combined with Beraprost.
Prasugrel The risk or severity of bleeding can be increased when Trapidil is combined with Prasugrel.
Sulodexide The risk or severity of bleeding can be increased when Trapidil is combined with Sulodexide.
Semuloparin The risk or severity of bleeding can be increased when Trapidil is combined with Semuloparin.
Idraparinux The risk or severity of bleeding can be increased when Trapidil is combined with Idraparinux.
Cangrelor The risk or severity of bleeding can be increased when Trapidil is combined with Cangrelor.
Astaxanthin The risk or severity of bleeding can be increased when Trapidil is combined with Astaxanthin.
Otamixaban The risk or severity of bleeding can be increased when Trapidil is combined with Otamixaban.
Amediplase The risk or severity of bleeding can be increased when Trapidil is combined with Amediplase.
Danaparoid The risk or severity of bleeding can be increased when Trapidil is combined with Danaparoid.
Dalteparin The risk or severity of bleeding can be increased when Trapidil is combined with Dalteparin.
Tinzaparin The risk or severity of bleeding can be increased when Trapidil is combined with Tinzaparin.
(R)-warfarin The risk or severity of bleeding can be increased when Trapidil is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Trapidil is combined with Ethyl biscoumacetate.
Nadroparin The risk or severity of bleeding can be increased when Trapidil is combined with Nadroparin.
Triflusal The risk or severity of bleeding can be increased when Trapidil is combined with Triflusal.
Ticagrelor The risk or severity of bleeding can be increased when Trapidil is combined with Ticagrelor.
Ditazole The risk or severity of bleeding can be increased when Trapidil is combined with Ditazole.
Vorapaxar The risk or severity of bleeding can be increased when Trapidil is combined with Vorapaxar.
Edoxaban The risk or severity of bleeding can be increased when Trapidil is combined with Edoxaban.
Sodium citrate The risk or severity of bleeding can be increased when Trapidil is combined with Sodium citrate.
Dextran The risk or severity of bleeding can be increased when Trapidil is combined with Dextran.
Bemiparin The risk or severity of bleeding can be increased when Trapidil is combined with Bemiparin.
Parnaparin The risk or severity of bleeding can be increased when Trapidil is combined with Parnaparin.
Desirudin The risk or severity of bleeding can be increased when Trapidil is combined with Desirudin.
Antithrombin Alfa The risk or severity of bleeding can be increased when Trapidil is combined with Antithrombin Alfa.
Protein C The risk or severity of bleeding can be increased when Trapidil is combined with Protein C.
Antithrombin III human The risk or severity of bleeding can be increased when Trapidil is combined with Antithrombin III human.
Letaxaban The risk or severity of bleeding can be increased when Trapidil is combined with Letaxaban.
Darexaban The risk or severity of bleeding can be increased when Trapidil is combined with Darexaban.
Betrixaban The risk or severity of bleeding can be increased when Trapidil is combined with Betrixaban.
Nafamostat The risk or severity of bleeding can be increased when Trapidil is combined with Nafamostat.
Monteplase The risk or severity of bleeding can be increased when Trapidil is combined with Monteplase.
Gabexate The risk or severity of bleeding can be increased when Trapidil is combined with Gabexate.
Fluindione The risk or severity of bleeding can be increased when Trapidil is combined with Fluindione.
Protein S human The risk or severity of bleeding can be increased when Trapidil is combined with Protein S human.
Brinase The risk or severity of bleeding can be increased when Trapidil is combined with Brinase.
Clorindione The risk or severity of bleeding can be increased when Trapidil is combined with Clorindione.
Diphenadione The risk or severity of bleeding can be increased when Trapidil is combined with Diphenadione.
Tioclomarol The risk or severity of bleeding can be increased when Trapidil is combined with Tioclomarol.
Melagatran The risk or severity of bleeding can be increased when Trapidil is combined with Melagatran.
Saruplase The risk or severity of bleeding can be increased when Trapidil is combined with Saruplase.
(S)-Warfarin The risk or severity of bleeding can be increased when Trapidil is combined with (S)-Warfarin.
Tocopherylquinone The risk or severity of bleeding can be increased when Trapidil is combined with Tocopherylquinone.
Dabigatran The risk or severity of bleeding can be increased when Trapidil is combined with Dabigatran.

Target Protein

Fibroblast growth factor receptor 3 FGFR3
Cyclic nucleotide phosphodiesterase PDE4A
Platelet-derived growth factor receptor beta PDGFRB

Referensi & Sumber

Artikel (PubMed)
  • PMID: 6894333
    Ohnishi H, Kosuzume H, Hayashi Y, Yamaguchi K, Suzuki Y, Itoh R: Effects of trapidil on thromboxane A2-induced aggregation of platelets, ischemic changes in heart and biosynthesis of thromboxane A2. Prostaglandins Med. 1981 Mar;6(3):269-81.
  • PMID: 6265246
    Azuma J, Sawamura A, Harada H, Tanimoto T, Morita Y, Sperelakis N, Yamamura Y: Trapidil stimulation of slow Ca2+ current in cardiac muscle. Eur J Pharmacol. 1981 Jun 19;72(2-3):199-208.
  • PMID: 6264257
    Ohnishi H, Yamaguchi K, Shimada S, Suzuki Y, Kumagai A: A new approach to the treatment of atherosclerosis and trapidil as an antagonist to platelet-derived growth factor. Life Sci. 1981 Apr 6;28(14):1641-6.
  • PMID: 6086387
    Mazurov AV, Menshikov MYu, Leytin VL, Tkachuk VA, Repin VS: Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil. FEBS Lett. 1984 Jul 9;172(2):167-71.
  • PMID: 21746798
    Catterall WA: Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 2011 Aug 1;3(8):a003947. doi: 10.1101/cshperspect.a003947.
  • PMID: 9461238
    Hoshiya M, Awazu M: Trapidil inhibits platelet-derived growth factor-stimulated mitogen-activated protein kinase cascade. Hypertension. 1998 Feb;31(2):665-71.
  • PMID: 21484090
    Johnston-Cox HA, Ravid K: Adenosine and blood platelets. Purinergic Signal. 2011 Sep;7(3):357-65. doi: 10.1007/s11302-011-9220-4. Epub 2011 Feb 8.
  • PMID: 8904615
    Harder S, Thurmann PA, Hellstern A, Benjaminov A: Pharmacokinetics of trapidil, an antagonist of platelet derived growth factor, in healthy subjects and in patients with liver cirrhosis. Br J Clin Pharmacol. 1996 Oct;42(4):443-9.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul